The Longitude Prize on ALS represents a pivotal moment in addressing one of the most challenging neurodegenerative diseases: amyotrophic lateral sclerosis (ALS). Caroline Purslow, Head of Health at Challenge Works, highlights the deeply personal story behind this initiative. The hope is to harness the power of artificial intelligence (AI) to revolutionize treatment and care for those battling this disease. A Personal Journey…

The use of artificial intelligence and big data in healthcare has advanced at remarkable speed over the past decade, rapidly reshaping how we diagnose, treat,

Tris Dyson, managing director of Challenge Works, about his diagnosis of ALS, the case for using a prize to spur innovation, and the potential for leveraging AI to find treatments for the disease.

A new international challenge prize has been launched to transform drug discovery for ALS, the most common form of MND through AI.

Podcast Episode · Live Life in Motion · 07/23/2025 · 56m

Mike Rogers, MND Association Director of Research and Innovation, looks at how data and AI could unlock new treatments.

One in 300 of us will develop motor neurone disease in our lifetime. It is a hideous disease that robs a person of their dignity and eventually their life.

What an incredible week! Thank you to everyone who helped make the launch of the #LongitudePrizeOnALS such a success — from the inspiring voices on stage, to the teams that made this Prize possible, ...

The new Longitude Prize aims to do what medicine has long struggled with: harness AI and global collaboration to unlock life-saving treatments for one of the most devastating diseases. Roger Highfield...

An artificial intelligence (AI) model is being trained on a set of NHS data for 57 million people in England, from which personal information has been stripped away. The pilot study is being run by re...